Niclosamide oral - CNPharm/Hyundai Bioscience
Latest Information Update: 17 May 2024
At a glance
- Originator Hyundai Bioscience
- Class Anthelmintics; Anti-inflammatories; Antibacterials; Antineoplastics; Antivirals; Benzamides; Chlorophenols; Nitrobenzenes; Skin disorder therapies; Small molecules
- Mechanism of Action Cell proliferation inhibitors; Mitochondrial oxidative phosphorylation uncouplers; MTOR protein inhibitors; Notch signalling pathway inhibitors; STAT3 transcription factor inhibitors; Virus internalisation inhibitors; Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Pancreatic cancer; Triple negative breast cancer